84579-82-8
Chemical Structure
NCO 700 sulfate
- CAS No.: 84579-82-8
- Formula:C26H41N3O12S
- Molecular Weight:619.68
IUPAC Name: ethyl (2R,3R)-3-(((S)-4-methyl-1-oxo-1-(4-(2,3,4-trimethoxybenzyl)piperazin-1-yl)pentan-2-yl)carbamoyl)oxirane-2-carboxylate sulfate
InChIKey: PDSSDIQJPXZWFP-NMSOQDRXSA-N
SMILES: S(=O)(=O)(O)O.C(N[C@H](C(=O)N1CCN(CC2=C(OC)C(OC)=C(OC)C=C2)CC1)CC(C)C)(=O)[C@H]3[C@H](C(OCC)=O)O3
Biological Activity: NCO-700 sulfate is a dual cathepsin B and calcium-activated neutral protease (CANP) inhibitor with IC50 values of 0.8 and 46 μM, respectively. NCO-700 sulfate reduces the degradation of myocardial fibrin by inhibiting protease activity. NCO-700 sulfate also has inhibitory effects on hormone-independent tumor cells, such as prostate cancer cells, and induces apoptosis. NCO-700 sulfate can be used to study myocardial ischemia and refractory hormone-independent tumors[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NCO 700 sulfate | NCO-700 sulfate is a dual cathepsin B and calcium-activated neutral protease (CANP) inhibitor with IC50 values of 0.8 and 46 μM, respectively. NCO-700 sulfate reduces the degradation of myocardial fibrin by inhibiting protease activity. NCO-700 sulfate also has inhibitory effects on hormone-independent tumor cells, such as prostate cancer cells, and induces apoptosis. NCO-700 sulfate can be used to study myocardial ischemia and refractory hormone-independent tumors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Toyo-oka T, et al. Reduction of experimentally produced acute myocardial infarction size by a new synthetic inhibitor, NCO-700, against calcium-activated neutral protease. Jpn Heart J. 1982 Sep;23(5):829-34. [Content Brief]
- [2]. Eilon GF, et al. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents. Cancer Chemother Pharmacol. 2000;45(3):183-91. [Content Brief]
